Last updated: February 20, 2026
What is OVIDREL and how is it positioned in the market?
OVIDREL (choriogonadotropin alfa) is a recombinant human chorionic gonadotropin used primarily in fertility treatments. It stimulates ovulation and supports early pregnancy, positioning itself as a key drug in assisted reproductive technology (ART).
Manufactured by EMD Serono, OVIDREL gained FDA approval in 2000. It competes mainly with urinary-derived hCG products such as Pregnyl and Novarel.
What are the market drivers influencing OVIDREL?
Several factors influence OVIDREL’s market share and growth potential:
- Increased infertility rates: Driven by delayed childbearing, rising obesity, and other factors. The CDC reports a US infertility prevalence of approximately 12% among women aged 15-44 as of 2020. Globally, infertility affects 8-12% of couples. This growth drives demand for ART drugs.
- Advancements in infertility treatments: Innovations in IVF and ovulation induction favor the use of recombinant products like OVIDREL over urinary-derived sources, due to consistent potency, purity, and lower contamination risk.
- Regulatory landscape: Approvals in emerging markets, including China and India, expand access. Divergent regulations may impact market penetration.
- Pricing and reimbursement policies: Insurers’ coverage favors recombinant products, often making them more attractive despite higher manufacturing costs.
- Preferential shift towards recombinant gonadotropins: Both physicians and patients increasingly favor recombinant over urinary products for safety and efficacy reasons.
How does OVIDREL compare to competitors?
| Feature |
OVIDREL |
Pregnyl/Novarel |
| Source |
Recombinant (human) |
Urinary-derived |
| Approval year |
2000 |
1959/1971 |
| Cost per dose (US) |
$300-$400 |
$150-$300 |
| Safety profile |
Lower contamination risk |
Higher variability |
| Consistency in potency |
High |
Variability possible |
Recombinant formulations like OVIDREL offer advantages in safety and batch-to-batch consistency, which increasingly influence prescriber preference.
What is the revenue trajectory forecast for OVIDREL?
While exact sales figures remain proprietary, estimates based on market analysis suggest:
- Historical revenue: Estimated in the range of $140-$180 million annually in the US and Europe (2019-2022).
- Growth prospects: CAGR projected at approximately 4-6% over the next five years, driven by increased infertility treatments and regulatory expansion.
- Market share: OVIDREL currently accounts for roughly 20-25% of the recombinant gonadotropin gonadotropin market segment, which is valued at $600 million globally.
Market outlook by region:
| Region |
Estimated Market Size (2022) |
Estimated OVIDREL Share |
Growth Rate (2023-2028) |
| North America |
$250 million |
25% |
4.5% |
| Europe |
$200 million |
22% |
3.8% |
| Asia-Pacific |
$100 million |
15% |
6.2% |
| Rest of world |
$50 million |
12% |
5.0% |
Emerging markets, particularly in Asia, could see accelerated adoption driven by expanding fertility clinics and local manufacturing approvals.
What are the risks impacting OVIDREL’s financial outlook?
Key risks include:
- Patent expiration: Original patents expired or are subject to challenges, increasing generic or biosimilar competition.
- Pricing pressures: Price sensitivity in cost-conscious markets may reduce margins.
- Regulatory hurdles: Changes may restrict access or delay approvals in key regions.
- Competitive innovations: Development of orally administered or novel gonadotropins could shift market preferences.
How does patent and regulatory status influence OVIDREL’s market stance?
As of 2023, OVIDREL’s core patents have largely expired. EMD Serono continues to hold exclusivity for certain formulations through data protections until 2026 in the US and later in other regions. Biosimilar entrants are on the rise; for instance, Sandoz announced biosimilar versions of recombinant gonadotropins, which could erode market share after patent expiry.
Regulatory approvals for biosimilars in the US and EU have increased, with several filings pending. Market entry of cheaper biosimilars will likely intensify price competition.
Closing analysis
OVIDREL remains a significant player in the fertility drug market, supported by the global increase in ART procedures and a shift toward recombinant formulations. The drug's revenue is projected to grow modestly, contingent on market expansion, biosimilar competition, and pricing strategies.
Key Takeaways
- OVIDREL is a recombinant hCG used in fertility treatments with steady demand driven by rising infertility rates.
- It faces competition from urinary-derived mimic drugs and biosimilars, which could impact pricing and sales.
- Market growth is expected between 4% and 6% annually over the next five years, with regional variations.
- Patent expiry and biosimilar entry pose near-term risks; however, ongoing regulatory and clinical differentiation sustain its market position.
FAQs
1. When did OVIDREL receive FDA approval?
In 2000.
2. What factors favor OVIDREL over urinary-derived alternatives?
Recombinant form offers higher safety, batch consistency, and lower contamination risks.
3. How might biosimilars impact OVIDREL’s sales?
Biosimilar competition could reduce prices and market share once patents expire, likely after 2026.
4. Which regions are experiencing the fastest growth for OVIDREL?
Asia-Pacific and other emerging markets show higher growth potential due to expanding fertility services.
5. What is the primary driver for increased demand of recombinant gonadotropins?
Physician and patient preference for safety, efficacy, and consistency over urinary-derived products.
References
- CDC. (2020). Data on infertility prevalence in the U.S.
- IQVIA. (2022). Global fertility drugs market report.
- EMD Serono. (2022). OVIDREL product information.
- Grand View Research. (2022). Fertility Drugs Market Size & Trends.
- EMA. (2022). Biosimilar approvals and regulations.
